美国 · SEC FORM 4
Celcuity Inc.
CELC · Nasdaq · CIK 0001603454 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
23 同一窗口内观察到的 Form 4 交易行
9 sales · 14 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-09-08 · BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 10,979,648
- 上期报告
- 11,360,367
- 日均成交量
- 995,703
- 回补天数
- 11.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-09-08 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | 买入 (P) | Common Stock | 170,100 | USD 56.27 | USD 9,571,302 | SEC 申报 ↗ |
| 2023-05-22 | Furcht Leo | 买入 (P) | Common Stock | 10,000 | USD 10.32 | USD 103,200 | SEC 申报 ↗ |
| 2022-12-09 | Sullivan Brian F. | 买入 (P) | Common Stock | 260,869 | USD 5.75 | USD 1,499,997 | SEC 申报 ↗ |
| 2022-11-22 | Murphy Polly A. | 买入 (P) | Common Stock | 5,000 | USD 9.68 | USD 48,400 | SEC 申报 ↗ |
| 2022-09-09 | NIGON RICHARD | 买入 (P) | Common Stock | 5,000 | USD 8.99 | USD 44,950 | SEC 申报 ↗ |
| 2022-05-25 | NIGON RICHARD | 买入 (P) | Common Stock | 754 | USD 5.94 | USD 4,479 | SEC 申报 ↗ |
Form 4 申报证据
38 transaction lines in the latest 365-day window; 115 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Furcht Leo | 期权行权/转换 (M) | Common Stock | 250 | USD 7.60 | USD 1,900 | SEC 申报 ↗ |
| 2026-10-01 | GRYSKA DAVID W | 奖励/授予 (A) | Common Stock | 893 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Sullivan Brian F. | 奖励/授予 (A) | Common Stock | 80,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Furcht Leo | 期权行权/转换 (M) | Common Stock | 250 | USD 7.60 | USD 1,900 | SEC 申报 ↗ |
| 2026-10-01 | GRYSKA DAVID W | 奖励/授予 (A) | Common Stock | 893 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Sullivan Brian F. | 奖励/授予 (A) | Common Stock | 80,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Laing Lance G. | 奖励/授予 (A) | Common Stock | 20,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-14 | Hahne Vicky | 奖励/授予 (A) | Common Stock | 16,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-14 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | 卖出 (S) | Common Stock | 3,100,000 | USD 102.50 | USD 317,750,000 | SEC 申报 ↗ |
| 2026-06-05 | ROMP CHARLES R | 奖励/授予 (A) | Common Stock | 1,530 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | NIGON RICHARD | 奖励/授予 (A) | Common Stock | 1,530 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Murphy Polly A. | 奖励/授予 (A) | Common Stock | 1,530 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Furcht Leo | 奖励/授予 (A) | Common Stock | 1,530 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Dalvey David | 奖励/授予 (A) | Common Stock | 1,530 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Buller Richard E | 奖励/授予 (A) | Common Stock | 1,530 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-02 | Laing Lance G. | 期权行权/转换 (M) | Common Stock | 1,000 | USD 9.89 | USD 9,890 | SEC 申报 ↗ |
| 2026-05-19 | Buller Richard E | 赠与 (G) | Common Stock | 1,029 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-04 | Dalvey David | 卖出 (S) | Common Stock | 25,000 | USD 140.68 | USD 3,517,000 | SEC 申报 ↗ |
| 2026-05-04 | Buller Richard E | 卖出 (S) | Common Stock | 9,000 | USD 140.47 | USD 1,264,197 | SEC 申报 ↗ |
| 2026-05-04 | Buller Richard E | 期权行权/转换 (M) | Common Stock | 9,000 | USD 5.10 | USD 45,900 | SEC 申报 ↗ |
| 2026-04-09 | NIGON RICHARD | 赠与 (G) | Common Stock | 10,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-11 | ROMP CHARLES R | 奖励/授予 (A) | Common Stock | 215 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-27 | Dalvey David | 卖出 (S) | Common Stock | 20,000 | USD 120.03 | USD 2,400,600 | SEC 申报 ↗ |
| 2025-12-15 | NIGON RICHARD | 赠与 (G) | Common Stock | 19,975 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-05 | Buller Richard E | 卖出 (S) | Common Stock | 3,000 | USD 105.69 | USD 317,077 | SEC 申报 ↗ |
| 2025-12-05 | Buller Richard E | 期权行权/转换 (M) | Common Stock | 3,000 | USD 5.50 | USD 16,500 | SEC 申报 ↗ |
| 2025-12-04 | Furcht Leo | 期权行权/转换 (M) | Common Stock | 250 | USD 7.60 | USD 1,900 | SEC 申报 ↗ |
| 2025-12-02 | Buller Richard E | 赠与 (G) | Common Stock | 500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-01 | Buller Richard E | 卖出 (S) | Common Stock | 1,100 | USD 98.13 | USD 107,943 | SEC 申报 ↗ |
| 2025-12-01 | Buller Richard E | 期权行权/转换 (M) | Common Stock | 1,100 | USD 14.83 | USD 16,313 | SEC 申报 ↗ |
| 2025-11-21 | Dalvey David | 卖出 (S) | Common Stock | 15,000 | USD 100.00 | USD 1,500,000 | SEC 申报 ↗ |
| 2025-11-20 | Buller Richard E | 卖出 (S) | Common Stock | 3,900 | USD 96.73 | USD 377,247 | SEC 申报 ↗ |
| 2025-11-20 | Buller Richard E | 期权行权/转换 (M) | Common Stock | 3,900 | USD 14.83 | USD 57,837 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CELC |
| CIK | 0001603454 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 8071 Services-Medical Laboratories |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 115 transaction lines from 2020-05-14 to 2026-10-07 9 P purchase lines · 55 S sale lines · 51 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.